

REMARKS

The specification has been amended to correct typographical errors which would be apparent to a person skilled in the art. The amendments to the specification are fully supported by the application as filed, see, *e.g.*, page 12, line 32 to page 13, line 30, and do not constitute new matter.

Claims 2, 3, 6, 9-30, 33-35, 37, 39, and 40 were pending in this application. Claims 2, 3, 6, 9-30, 33-35, 37, 39, and 40 have been canceled without prejudice. Applicant reserves the right to prosecute the subject matter of the canceled claims in the present application and/or one or more related applications. New claims 42 to 82 have been added. The new claims are fully supported by the specification, see, *e.g.*, the table below for examples of support in the specification for the new claims.

Claim No.	Examples of Support in Specification
42	p. 9, <i>ll.</i> 20-23; p. 9, <i>l.</i> 27 to p. 10, <i>l.</i> 2; p. 28, <i>l.</i> 22 to p. 29, <i>l.</i> 1; p. 32, <i>ll.</i> 20-25; p. 83, <i>l.</i> 23 to p. 84, <i>l.</i> 27
43	p. 84, <i>ll.</i> 21-25
44	p. 84, <i>ll.</i> 10-25
45	p. 43, <i>l.</i> 28 to p. 44, <i>l.</i> 18
46	p. 10, <i>l.</i> 3 to p. 11, <i>l.</i> 6
47	p. 10, <i>ll.</i> 6-13; p. 11, <i>ll.</i> 7-15
48	p. 10, <i>ll.</i> 13-18
49	p. 10, <i>ll.</i> 18-22
50	p. 13, <i>ll.</i> 1-7
51	p. 15, <i>ll.</i> 17-32; p. 73, <i>l.</i> 27 to p. 74, <i>l.</i> 6
52	p. 15, <i>ll.</i> 17-32; p. 73, <i>l.</i> 27 to p. 74, <i>l.</i> 6
53	p. 13, <i>ll.</i> 1-14; p. 68, <i>l.</i> 29 to p. 68, <i>l.</i> 9
54	p. 13, <i>ll.</i> 9-11; p. 15, <i>ll.</i> 28-30; p. 69, <i>ll.</i> 3-6; p. 73, <i>l.</i> 34 to p. 74, <i>l.</i> 3
55	p. 13, <i>ll.</i> 12-14; p. 15, <i>ll.</i> 30-32; p. 69, <i>ll.</i> 6-9; p. 74, <i>ll.</i> 3-6
56	p. 13, <i>ll.</i> 14-21; p. 15, <i>l.</i> 33 to p. 14, <i>l.</i> 6
57	p. 15, <i>l.</i> 33 to p. 14, <i>l.</i> 16
58	p. 15, <i>l.</i> 33 to p. 14, <i>l.</i> 16; p. 74, <i>ll.</i> 7-23
59	p. 13, <i>ll.</i> 14-30; p. 69, <i>ll.</i> 10-26; p. 74, <i>ll.</i> 7-23
60	p. 13 <i>ll.</i> 23-26, p. 16, <i>ll.</i> 9-12; p. 69, <i>ll.</i> 19-23; p. 74, <i>ll.</i> 17-20
61	p. 13, <i>ll.</i> 26-20; p. 16, <i>ll.</i> 12-16; p. 69, <i>ll.</i> 23-26; p. 74, <i>ll.</i> 20-23
62	p. 12, <i>ll.</i> 1-9; p. 37, <i>l.</i> 24 to p. 43, <i>l.</i> 26
63	p. 12, <i>ll.</i> 10-31; p. 32, <i>ll.</i> 5-7
64	p. 12, <i>ll.</i> 10-31; p. 31, <i>l.</i> 22 to p. 32, <i>l.</i> 5; p. 49, <i>ll.</i> 25-28; p. 54, <i>ll.</i> 24-26
65	p. 12, <i>ll.</i> 10-31, p. 32, <i>ll.</i> 5-7
66	p. 12, <i>ll.</i> 10-31; p. 31, <i>ll.</i> 22 to p. 32, <i>l.</i> 5; p. 54, <i>ll.</i> 24-26
67-70	p. 21, <i>ll.</i> 26-34

Claim No.	Examples of Support in Specification
71, 74, 77, 80	p. 97, ll. 1-11
72, 73, 75, 76, 78, 79, 81, 82	p. 28, ll. 15-21

Thus, no new matter has been added. After entry of the present Amendment, claims 42 to 82 will be pending in the instant application.

The Examiner has required species elections under 35 U.S.C. § 121. In particular, the Examiner has required that Applicant elect a single species from each of the following:

- A. Methods comprising a nucleic acid comprising (a) a reporter gene, (b) a substrate labeled with a fluorophore and a quencher, or (c) a substrate labeled with a fluorescent donor moiety and a fluorescent acceptor moiety.
- B. A method for (a) identifying a compound that modulates fungal tRNA splicing endonuclease, or (b) a method of identifying a therapeutic agent for treatment, management, or amelioration of fungal infection or a symptom thereof.
- C. A particular and specific reporter gene, wherein said gene comprises a tRNA intron.
- D. Methods comprising a particular and specific substrate.
- E. Methods comprising compounds that (a) inhibit activity, or (b) enhance activity.
- F. A particular compound from a combinatorial library.
- G. Methods wherein the compound (a) binds to the fungal tRNA splicing endonuclease, (b) binds to the substrate, or (c) binds to the tRNA intron.
- H. Methods comprising determination of (a) cytotoxic activity of the compound, or (b) cytostatic activity of the compound.

In response, Applicant hereby elects the following:

- A. Methods comprising a nucleic acid comprising a reporter gene.
- B. A method for identifying a compound that modulates fungal tRNA splicing endonuclease.
- C. Luciferase as a reporter gene.
- D. A bulge-helix-bulge structure.
- E. Methods comprising compounds that inhibit activity.
- F. Small organic molecules that are isoprenoid analogs.
- G. Methods wherein the compound binds to the fungal tRNA splicing endonuclease.
- H. Methods comprising determination of cytotoxic activity the compound.

Applicant believes that claims 42, 43, 45, 46, 47, 48, 62, 63, 64, 65 and 66 read on the elected species.

Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application.

Respectfully submitted,

Date: July 15, 2008

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)
Jones Day
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

By: Jennifer J. Akeda
Reg. No. 46,617